
Johnson & Johnson’s Up and Down Pharma PR News
News that a subsidiary of US drug giant Johnson & Johnson will be forced to pay $181 Million to settle state allegations against the company’s marketing of Risperdal, will be somewhat offset by news of deal with Danish pharmaceutical group Genmab. Johnson & Johnson is set to pen a news